dalteparin has been researched along with Atrial Fibrillation in 96 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation and is associated with less bleeding than well controlled warfarin therapy." | 9.22 | Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. ( Al-Saady, N; Batushkin, V; de Groot, JR; Ezekowitz, MD; Fernandez, V; Goette, A; Grosso, MA; Jin, J; Kushnir, M; Lip, GY; Melino, M; Mercuri, MF; Merino, JL; Merkely, B; Pelekh, N; Spinar, J; Zamoryakhin, D; Zenin, S, 2016) |
| "125 patients with atrial fibrillation or -flutter received dalteparin for a median of 11 days (range of 3-41 days)." | 9.10 | Anticoagulation with the low-molecular-weight heparin dalteparin (Fragmin) in atrial fibrillation and TEE-guided cardioversion. ( Bechtold, H; Fung, S; Gunzenhauser, D; Janssen, D; Sawitzki, H, 2003) |
| "The present data do not provide any evidence that LMWH is superior to aspirin for the treatment of acute ischaemic stroke in patients with atrial fibrillation." | 9.09 | Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. ( Abdelnoor, M; Berge, E; Nakstad, PH; Sandset, PM, 2000) |
| "Warfarin is a widely used oral anticoagulant drug that has rarely been associated with leukocytoclastic vasculitis and allergic interstitial nephritis." | 5.56 | Ulcerative IgA vasculitis in the setting of warfarin therapy. ( Akay, BN; Boyvat, A; Heper, A; Kalay-Yildizhan, I, 2020) |
| "To determine the efficacy and safety of dalteparin postoperative bridging treatment versus placebo for patients with atrial fibrillation or mechanical heart valves when warfarin is temporarily interrupted for a planned procedure." | 5.41 | Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial. ( Anderson, DR; Bates, SM; Blostein, M; Kahn, SR; Kearon, C; Kovacs, MJ; Lazo-Langner, A; Ramsay, T; Rodger, MA; Sabri, E; Schulman, S; Solymoss, S; Wells, PS; Yeo, E, 2021) |
| "BRIDGE was a randomized, double-blind, placebo-controlled trial of bridge therapy with dalteparin 100 IU/kg twice daily in patients with atrial fibrillation requiring warfarin interruption." | 5.27 | Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial. ( Clark, NP; Douketis, JD; Hasselblad, V; Kindzelski, AL; Ortel, TL; Schulman, S, 2018) |
| "Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation and is associated with less bleeding than well controlled warfarin therapy." | 5.22 | Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. ( Al-Saady, N; Batushkin, V; de Groot, JR; Ezekowitz, MD; Fernandez, V; Goette, A; Grosso, MA; Jin, J; Kushnir, M; Lip, GY; Melino, M; Mercuri, MF; Merino, JL; Merkely, B; Pelekh, N; Spinar, J; Zamoryakhin, D; Zenin, S, 2016) |
| "To estimate, from the perspective of Statutory Health Insurance (SHI, third-party payer) in Germany, the economic consequences of using the subcutaneous low-molecular-weight heparin (LMWH) enoxaparin instead of intravenous unfractionated heparin followed by oral phenprocoumon (UFH/PPC) for anticoagulation in patients undergoing transesophageal echocardiography (TEE)-guided early electrical cardioversion (ECV) of persisting nonvalvular atrial fibrillation (AF) without intracardiac clot." | 5.12 | Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany. ( Brecht, JG; Huppertz, E; Lehmacher, W; Nixdorff, U; Schädlich, PK; Schmidt-Lucke, C; Stellbrink, C, 2007) |
| "Enoxaparin is noninferior to UFH+phenprocoumon for prevention of ischemic and embolic events, bleeding complications, and death in TEE-guided cardioversion of atrial fibrillation." | 5.11 | Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) ( Daniel, WG; Geller, C; Hanrath, P; Hofmann, T; Lehmacher, W; Mügge, A; Nixdorff, U; Schmidt-Lucke, C; Schmidt-Lucke, JA; Sehnert, W; Stellbrink, C, 2004) |
| "Thirty-three patients with atrial fibrillation were randomly treated either with OAT (warfarin 10, 7." | 5.10 | Is there a hypercoagulable phase during initiation of antithrombotic therapy with oral anticoagulants in patients with atrial fibrillation? ( Husted, SE; Lassen, JF; Zeuthen, EL, 2003) |
| "125 patients with atrial fibrillation or -flutter received dalteparin for a median of 11 days (range of 3-41 days)." | 5.10 | Anticoagulation with the low-molecular-weight heparin dalteparin (Fragmin) in atrial fibrillation and TEE-guided cardioversion. ( Bechtold, H; Fung, S; Gunzenhauser, D; Janssen, D; Sawitzki, H, 2003) |
| "The present data do not provide any evidence that LMWH is superior to aspirin for the treatment of acute ischaemic stroke in patients with atrial fibrillation." | 5.09 | Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. ( Abdelnoor, M; Berge, E; Nakstad, PH; Sandset, PM, 2000) |
| "In the pooled analysis of individual patient data comparing dabigatran with warfarin (SPAF and venous thromboembolism treatment indications), myocardial infarction occurrence favored warfarin (odds ratio [OR] 1." | 4.89 | Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. ( Clemens, A; Fraessdorf, M; Friedman, J, 2013) |
| " We included patients aged ≥ 18 years with incident stroke diagnosis and assessed prophylactic use of anticoagulants in the 30 days following hospital discharge including low-molecular-weight heparin (enoxaparin ≤40 mg/day, dalteparin ≤5000 IU/day), unfractionated heparin ≤5000 IU/ twice daily or 3 times a day, apixaban 2." | 4.12 | Trends in post-discharge prophylactic anticoagulant use among stroke patients in the United States between 2006 and 2019. ( Cuker, A; Dawwas, GK; Hennessy, S; Rothstein, A, 2022) |
| "ENSURE-AF (NCT02072434) assessed therapy with edoxaban vs enoxaparin-warfarin in patients with nonvalvular atrial fibrillation (AF) undergoing elective electrical cardioversion (ECV)." | 3.96 | Comparing TEE- vs Non-TEE-guided cardioversion of atrial fibrillation: The ENSURE-AF trial. ( De Caterina, R; Goette, A; Huber, K; Jin, J; Kozieł, M; Lip, GYH; Melino, M; Merino, JL, 2020) |
| "We evaluated the hypothesis that a relationship exists between inflammation and the outcome of pharmaceutical cardioversion with amiodarone in recent onset atrial fibrillation." | 3.74 | Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome. ( Dragomanovits, S; Kalogeropoulos, AS; Kremastinos, DT; Papathanasiou, S; Rigopoulos, AG; Rizos, I; Sakadakis, EA; Tsiodras, S, 2007) |
| "Over 2 million patients in North America are on warfarin anticoagulation therapy for prevention of thromboembolism." | 3.73 | Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol. ( Ahmed, M; Bragg, L; Brotman, DJ; Jaffer, AK; Klein, A; Qadeer, MA; Seshadri, N, 2005) |
| "Adult patients with cancer at the time they develop thrombosis." | 3.01 | Anticoagulant Therapy for Cancer-Associated Thrombosis : A Cost-Effectiveness Analysis. ( Eckman, MH; Gulati, S, 2023) |
| "Major bleeding was observed in nine of 260 patients (3." | 2.73 | Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). ( Dunn, AS; Spyropoulos, AC; Turpie, AG, 2007) |
| "Minor bleeding was defined as hematoma that did not require intervention." | 2.73 | Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. ( Arruda, M; Barrett, C; Beheiry, S; Cummings, J; Di Biase, L; Fahmy, T; Hao, S; Kanj, M; Martin, DO; Natale, A; Patel, D; Saliba, W; Schweikert, R; Wazni, OM, 2007) |
| "Search terms included "Lemierre Syndrome" AND "anticoagulation" NOT "prophylaxis" OR "atrial fibrillation," in addition to a list of parenteral and oral anticoagulants." | 2.72 | Anticoagulation Strategies in the Management of Lemierre Syndrome: A Systematic Review of the Literature. ( Adedeji, A; Chukwura, O; McNulty, SB; Obafemi, T; Reinert, JP, 2021) |
| " Three enoxaparin dosing strategies had been prescribed: therapeutic, prophylactic, or adjusted." | 2.71 | Prescribing patterns and outcomes of enoxaparin for anticoagulation of atrial fibrillation. ( Adamson, R; Khazan, M; Mathis, AS; Scheuering, S, 2003) |
| " Further investigations as a basis of general recommendations on standard dosing regimen are outstanding for use of each LMWH in percutaneous coronary interventions, as combination with Glycoprotein IIb/IIIa-inhibitors, in acute myocardial infarction and in artificial heart valves." | 2.42 | Anticoagulation with low-molecular-weight heparin in patients with heart diseases. ( Bechtold, H; Janssen, D, 2004) |
| "Warfarin is a widely used oral anticoagulant drug that has rarely been associated with leukocytoclastic vasculitis and allergic interstitial nephritis." | 1.56 | Ulcerative IgA vasculitis in the setting of warfarin therapy. ( Akay, BN; Boyvat, A; Heper, A; Kalay-Yildizhan, I, 2020) |
| "Cancer is a known hypercoagulable state that leads to an increased risk of venous thromboembolism (VTE)." | 1.48 | Anticoagulation prescribing patterns in patients with cancer. ( Ahuja, T; Cirrone, F; Green, D; Papadopoulos, J; Raco, V; Xiang, E, 2018) |
| "Aspirin (53." | 1.43 | Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience. ( Fahed, E; Ghauche, J; Maarrawi, J; Menassa-Moussa, L; Moussa, R; Nohra, G; Okais, N; Rahme, R; Rizk, T; Samaha, E, 2016) |
| "Dabigatran has demonstrated similar efficacy and safety to enoxaparin for VTE prevention in patients undergoing hip and knee arthroplasty, and to warfarin for the treatment of VTE." | 1.42 | The evolving role of dabigatran etexilate in clinical practice. ( Drambarean, B; Hellenbart, E; Lee, J; Nutescu, EA, 2015) |
| "Dabigatran was stopped and dalteparin 5000 International Units/bid and 40 μg alprostadil infusions were started." | 1.38 | Fatal basilar artery occlusion under dabigatran occurring 13 days after femoral embolectomy. ( Finsterer, J; Reiter, M; Schäffl-Doweik, L; Stöllberger, C, 2012) |
| "Systemic thromboembolism is a severe complication in patients undergoing electrical cardioversion (ECV) for atrial fibrillation (AF)." | 1.37 | Low molecular weight heparin (parnaparin) for cardioembolic events prevention in patients with atrial fibrillation undergoing elective electrical cardioversion: a prospective cohort study. ( Alberti, S; Angeloni, G; Banzato, A; Cucchini, U; Formichi, M; Pengo, V; Romagnoli, E, 2011) |
| "Three patients with thrombus had paroxysmal AF with normal LV function." | 1.36 | Prevalence and clinical characteristics associated with left atrial appendage thrombus in fully anticoagulated patients undergoing catheter-directed atrial fibrillation ablation. ( Atwater, BD; Bahnson, TD; Crowley, AL; Daubert, JP; Hranitzky, PM; Voora, D; Wallace, TW, 2010) |
| " Previous evidence has shown that these drugs are safe and effective in this indication." | 1.35 | AFFECT: a prospective, open-label, multicenter trial to evaluate the feasibility and safety of a short-term treatment with subcutaneous certoparin in patients with persistent non-valvular atrial fibrillation. ( Adams, J; Appel, KF; Eggers, E; Haake, H; Harenberg, J; Heuer, H; Oeckinghaus, R; Seidel, K; Tebbe, U, 2008) |
| "The other two patients with history of pulmonary embolism, and one patient having mechanical aortic valve and atrial fibrillation, recovered uneventfully when reduced doses of low molecular weight heparin bridging therapy were administered." | 1.35 | The Janus face of thromboprophylaxis in patients with high risk for both thrombosis and bleeding during intracranial surgery: report of five exemplary cases. ( Armstrong, E; Hernesniemi, J; Niemi, T; Silvasti-Lundell, M, 2009) |
| "Preprocedural TEE revealed LA thrombus in 12 of 732 cases (1." | 1.35 | Incidence and predictors of left atrial thrombus prior to catheter ablation of atrial fibrillation. ( Abraham, TP; Berger, RD; Calkins, H; Cheng, A; Chilukuri, K; Dalal, D; Dong, J; Henrikson, CA; Marine, JE; Nazarian, S; Scherr, D; Spragg, D, 2009) |
| "Acute myocardial infarction is a rare complication of mitral stenosis." | 1.33 | Acute myocardial infarction in a patient with severe unrecognized mitral stenosis. ( Bajraktari, G; Beqiri, A; Berisha, I; Elezi, S; Kastrati, S; Manaj, R; Thaqi, S, 2006) |
| "Rupture of a pseudoaneurysm can be catastrophic." | 1.33 | Ruptured femoral pseudoaneurysm presenting as a lateral abdominal wall hematoma. ( Ma, M; Snook, CP, 2005) |
| "Subchorionic hematoma is a potentially serious complication that can occur in pregnant patients receiving enoxaparin for the prevention of thromboembolism." | 1.33 | Massive subchorionic hematoma associated with enoxaparin. ( Goodwin, TM; Lee, RH, 2006) |
| "When a hematoma is large, the initial clinical picture may include hypovolemic shock, which may develop during surgery if the hematoma is not diagnosed early." | 1.33 | [Hypovolemic shock during surgery caused by a rectus sheath hematoma]. ( García, R; López-Escobar, M; Medina, C; Torres, LM; Vidal, MA, 2005) |
| " All patients received enoxaparin at a dosage of 100 IU antiXa/kg twice daily before undergoing multiplane TEE." | 1.31 | A new therapeutic strategy for electrical cardioversion of atrial fibrillation. ( de Luca, I; de Luca, L; Del Salvatore, B; Sorino, M, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 53 (55.21) | 29.6817 |
| 2010's | 31 (32.29) | 24.3611 |
| 2020's | 12 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Spronk, HM | 1 |
| De Jong, AM | 1 |
| Verheule, S | 1 |
| De Boer, HC | 1 |
| Maass, AH | 1 |
| Lau, DH | 1 |
| Rienstra, M | 1 |
| van Hunnik, A | 1 |
| Kuiper, M | 1 |
| Lumeij, S | 1 |
| Zeemering, S | 1 |
| Linz, D | 1 |
| Kamphuisen, PW | 1 |
| Ten Cate, H | 1 |
| Crijns, HJ | 1 |
| Van Gelder, IC | 1 |
| van Zonneveld, AJ | 1 |
| Schotten, U | 1 |
| Nuno-Gonzalez, A | 1 |
| Calzado-Villarreal, L | 1 |
| Gutierrez-Pascual, M | 1 |
| Gamo-Villegas, R | 1 |
| Sanz-Robles, H | 1 |
| Sanchez-Gilo, A | 1 |
| Pinedo-Moraleda, F | 1 |
| Lopez-Estebaranz, JL | 1 |
| Vidal, MA | 1 |
| López-Escobar, M | 1 |
| Medina, C | 1 |
| García, R | 1 |
| Torres, LM | 1 |
| Bajraktari, G | 1 |
| Kastrati, S | 1 |
| Manaj, R | 1 |
| Berisha, I | 1 |
| Thaqi, S | 1 |
| Beqiri, A | 1 |
| Elezi, S | 1 |
| Kosior, DA | 1 |
| Torbicki, A | 1 |
| Opolski, G | 1 |
| Potter, J | 1 |
| Angeloni, G | 1 |
| Alberti, S | 1 |
| Romagnoli, E | 1 |
| Banzato, A | 1 |
| Formichi, M | 1 |
| Cucchini, U | 1 |
| Pengo, V | 1 |
| Oldham, M | 1 |
| Palkimas, S | 1 |
| Hedrick, A | 1 |
| Dawwas, GK | 1 |
| Cuker, A | 1 |
| Rothstein, A | 1 |
| Hennessy, S | 1 |
| Gulati, S | 1 |
| Eckman, MH | 1 |
| Batakji, M | 1 |
| Theodore, D | 1 |
| Chen, S | 1 |
| Schmidt, B | 1 |
| Tohoku, S | 1 |
| Trolese, L | 1 |
| Bordignon, S | 1 |
| Chun, KRJ | 1 |
| Kulkarni, SA | 1 |
| Fang, MC | 1 |
| Kozieł, M | 1 |
| Merino, JL | 2 |
| De Caterina, R | 1 |
| Huber, K | 1 |
| Jin, J | 2 |
| Melino, M | 2 |
| Goette, A | 3 |
| Lip, GYH | 1 |
| Adedeji, A | 1 |
| Chukwura, O | 1 |
| Obafemi, T | 1 |
| McNulty, SB | 1 |
| Reinert, JP | 1 |
| Kalay-Yildizhan, I | 1 |
| Akay, BN | 1 |
| Boyvat, A | 1 |
| Heper, A | 1 |
| Oh, TH | 1 |
| Jung, H | 1 |
| Lee, Y | 1 |
| Oh, HJ | 1 |
| Ryu, KH | 1 |
| Park, BJ | 1 |
| Yoon, BH | 1 |
| Elias, A | 1 |
| Morgenstern, Y | 1 |
| Braun, E | 1 |
| Brenner, B | 1 |
| Tzoran, I | 1 |
| Lin, AN | 1 |
| Lin, S | 1 |
| Lin, K | 1 |
| Gokhroo, R | 1 |
| Hwang, HG | 1 |
| Koo, SM | 1 |
| Uh, ST | 1 |
| Kim, YK | 1 |
| Guedeney, P | 1 |
| Hammoudi, N | 1 |
| Duthoit, G | 1 |
| Yan, Y | 1 |
| Silvain, J | 1 |
| Pousset, F | 1 |
| Isnard, R | 1 |
| Redheuil, A | 1 |
| Kerneis, M | 1 |
| Collet, JP | 1 |
| Montalescot, G | 1 |
| Xiang, E | 1 |
| Ahuja, T | 1 |
| Raco, V | 1 |
| Cirrone, F | 1 |
| Green, D | 1 |
| Papadopoulos, J | 1 |
| Sainz-Gaspar, L | 1 |
| Pita da Veiga, G | 1 |
| Suárez-Peñaranda, JM | 1 |
| Vázquez-Veiga, H | 1 |
| Sánchez-Aguilar, D | 1 |
| Klein, HH | 1 |
| Clemens, A | 1 |
| Fraessdorf, M | 1 |
| Friedman, J | 1 |
| Darwish, OS | 1 |
| Strube, S | 1 |
| Nguyen, HM | 1 |
| Tanios, MA | 1 |
| Roberts, A | 1 |
| Mooney, T | 1 |
| Joseph, P | 1 |
| Salemis, NS | 1 |
| Oikonomakis, I | 1 |
| Lagoudianakis, E | 1 |
| Boubousis, G | 1 |
| Tsakalakis, C | 1 |
| Sourlas, S | 1 |
| Gourgiotis, S | 1 |
| Revigliono, JI | 1 |
| Cornavaca, T | 1 |
| Becerra, F | 1 |
| Albertini, R | 1 |
| Contreras, AE | 1 |
| Tabares, A | 1 |
| Hellenbart, E | 1 |
| Drambarean, B | 1 |
| Lee, J | 1 |
| Nutescu, EA | 1 |
| Fahed, E | 1 |
| Ghauche, J | 1 |
| Rahme, R | 1 |
| Okais, N | 1 |
| Samaha, E | 1 |
| Nohra, G | 1 |
| Rizk, T | 1 |
| Maarrawi, J | 1 |
| Menassa-Moussa, L | 1 |
| Moussa, R | 1 |
| Ezekowitz, MD | 2 |
| Zamoryakhin, D | 1 |
| Mercuri, MF | 1 |
| Grosso, MA | 1 |
| Fernandez, V | 1 |
| Al-Saady, N | 1 |
| Pelekh, N | 1 |
| Merkely, B | 1 |
| Zenin, S | 1 |
| Kushnir, M | 1 |
| Spinar, J | 1 |
| Batushkin, V | 1 |
| de Groot, JR | 1 |
| Lip, GY | 1 |
| Elliott, DJ | 1 |
| Zhao, L | 2 |
| Jasper, SE | 5 |
| Lieber, EA | 3 |
| Klein, AL | 5 |
| Weintraub, WS | 1 |
| Hoppensteadt, D | 1 |
| Fareed, J | 1 |
| Apperson-Hansen, C | 2 |
| Katz, WE | 3 |
| Malouf, JF | 3 |
| Stoddard, MF | 3 |
| Pape, LA | 2 |
| Scherr, D | 2 |
| Dalal, D | 2 |
| Chilukuri, K | 2 |
| Dong, J | 1 |
| Spragg, D | 2 |
| Henrikson, CA | 2 |
| Nazarian, S | 2 |
| Cheng, A | 2 |
| Berger, RD | 1 |
| Abraham, TP | 1 |
| Calkins, H | 2 |
| Marine, JE | 2 |
| Prudente, LA | 1 |
| Moorman, JR | 1 |
| Lake, D | 1 |
| Xiao, Y | 1 |
| Greebaum, H | 1 |
| Mangrum, JM | 1 |
| DiMarco, JP | 1 |
| Ferguson, JD | 1 |
| Bui, HT | 1 |
| Krisnaswami, A | 1 |
| Le, CU | 1 |
| Chan, J | 1 |
| Shenoy, BN | 1 |
| Dobrev, D | 1 |
| Ravens, U | 1 |
| Hammerstingl, C | 2 |
| Schmitz, A | 1 |
| Fimmers, R | 1 |
| Omran, H | 2 |
| Wallace, TW | 1 |
| Atwater, BD | 1 |
| Daubert, JP | 1 |
| Voora, D | 1 |
| Crowley, AL | 1 |
| Bahnson, TD | 1 |
| Hranitzky, PM | 1 |
| Ahmed, I | 1 |
| Gertner, E | 1 |
| Nelson, WB | 1 |
| House, CM | 1 |
| Dahiya, R | 1 |
| Anderson, CP | 1 |
| Benditt, DG | 1 |
| Zhu, DW | 1 |
| Sorajja, D | 1 |
| Bhakta, MD | 1 |
| Altemose, GT | 1 |
| Mayer, SA | 1 |
| Abraham, T | 1 |
| Sinha, S | 1 |
| Berger, R | 1 |
| Leithäuser, B | 1 |
| Kasch, F | 1 |
| Broemel, T | 1 |
| Park, JW | 1 |
| Stöllberger, C | 1 |
| Reiter, M | 1 |
| Schäffl-Doweik, L | 1 |
| Finsterer, J | 1 |
| Biteker, M | 1 |
| Tekkeşin, Aİ | 1 |
| Can, MM | 1 |
| Dayan, A | 1 |
| Ilhan, E | 1 |
| Türkmen, FM | 1 |
| Khazan, M | 1 |
| Scheuering, S | 1 |
| Adamson, R | 1 |
| Mathis, AS | 1 |
| Schmidt, H | 1 |
| von der Recke, G | 1 |
| Paar, WD | 2 |
| Lüderitz, B | 1 |
| Scharf, Y | 1 |
| Hershkoviz, R | 1 |
| Stellbrink, C | 5 |
| Nixdorff, U | 4 |
| Hofmann, T | 3 |
| Lehmacher, W | 3 |
| Daniel, WG | 2 |
| Hanrath, P | 3 |
| Geller, C | 1 |
| Mügge, A | 2 |
| Sehnert, W | 1 |
| Schmidt-Lucke, C | 3 |
| Schmidt-Lucke, JA | 3 |
| Bechtold, H | 3 |
| Janssen, D | 2 |
| Khan, FY | 1 |
| Hassan, IF | 1 |
| Allity, MH | 1 |
| Khan, SM | 1 |
| de Luca, I | 3 |
| Sorino, M | 3 |
| De Luca, L | 3 |
| Colonna, P | 2 |
| Del Salvatore, B | 2 |
| Corlianò, L | 1 |
| Ma, M | 1 |
| Snook, CP | 1 |
| Preobrazhenskiĭ, DV | 1 |
| Sidorenko, BA | 1 |
| Kiktev, VG | 1 |
| Batyraliev, TA | 1 |
| Pershukov, IV | 1 |
| Jaffer, AK | 1 |
| Ahmed, M | 1 |
| Brotman, DJ | 1 |
| Bragg, L | 1 |
| Seshadri, N | 1 |
| Qadeer, MA | 1 |
| Klein, A | 2 |
| Verheugt, FW | 2 |
| Meurer, J | 1 |
| Grewe, R | 2 |
| Klein, HU | 1 |
| Jabr, FI | 1 |
| Lee, RH | 1 |
| Goodwin, TM | 1 |
| Schädlich, PK | 1 |
| Huppertz, E | 1 |
| Brecht, JG | 1 |
| Dunn, AS | 1 |
| Spyropoulos, AC | 1 |
| Turpie, AG | 2 |
| Tebbe, U | 2 |
| Rizos, I | 1 |
| Tsiodras, S | 1 |
| Rigopoulos, AG | 1 |
| Dragomanovits, S | 1 |
| Kalogeropoulos, AS | 1 |
| Papathanasiou, S | 1 |
| Sakadakis, EA | 1 |
| Kremastinos, DT | 1 |
| Wazni, OM | 1 |
| Beheiry, S | 1 |
| Fahmy, T | 1 |
| Barrett, C | 1 |
| Hao, S | 1 |
| Patel, D | 1 |
| Di Biase, L | 1 |
| Martin, DO | 1 |
| Kanj, M | 1 |
| Arruda, M | 1 |
| Cummings, J | 1 |
| Schweikert, R | 1 |
| Saliba, W | 1 |
| Natale, A | 1 |
| Carerj, S | 1 |
| Oliva, E | 1 |
| De Tommasi, SM | 1 |
| Conti, U | 1 |
| Iacopi, F | 1 |
| D'Agostino, C | 1 |
| D'Amato, N | 1 |
| Pettinati, G | 1 |
| Montericcio, V | 1 |
| Cualbu, A | 1 |
| Zhang, Z | 1 |
| Kolm, P | 1 |
| Jasper, S | 1 |
| Lewis, C | 1 |
| Weintraub, W | 1 |
| Smoot, EC | 1 |
| Murray, RD | 2 |
| Shah, A | 2 |
| Goodman, A | 1 |
| Deitcher, SR | 2 |
| Grimm, RA | 2 |
| Bashir, M | 1 |
| Kühle, K | 1 |
| Fetsch, T | 1 |
| Eisele, R | 1 |
| Melzer, N | 1 |
| Englert, C | 1 |
| Bramlage, P | 1 |
| Spannagl, M | 1 |
| Oeckinghaus, R | 1 |
| Appel, KF | 1 |
| Heuer, H | 1 |
| Haake, H | 1 |
| Eggers, E | 1 |
| Seidel, K | 1 |
| Adams, J | 1 |
| Harenberg, J | 1 |
| Kovacs, MJ | 2 |
| Wells, PS | 2 |
| Anderson, DR | 2 |
| Lazo-Langner, A | 1 |
| Kearon, C | 2 |
| Bates, SM | 2 |
| Blostein, M | 1 |
| Kahn, SR | 2 |
| Schulman, S | 2 |
| Sabri, E | 1 |
| Solymoss, S | 2 |
| Ramsay, T | 1 |
| Yeo, E | 1 |
| Rodger, MA | 1 |
| Clark, NP | 1 |
| Douketis, JD | 1 |
| Hasselblad, V | 1 |
| Kindzelski, AL | 1 |
| Ortel, TL | 1 |
| Luzi, M | 1 |
| Capucci, A | 1 |
| Di Pasquale, G | 1 |
| Zagnoni, S | 1 |
| Niemi, T | 1 |
| Silvasti-Lundell, M | 1 |
| Armstrong, E | 1 |
| Hernesniemi, J | 1 |
| Wandeler-Meyer, K | 1 |
| Bremerich, J | 1 |
| Christ, M | 1 |
| Kim, MH | 1 |
| Morady, F | 1 |
| Conlon, B | 1 |
| Kronick, S | 1 |
| Lowell, M | 1 |
| Bruckman, D | 1 |
| Armstrong, WF | 1 |
| Eagle, KA | 1 |
| Wakai, A | 1 |
| Zeuthen, EL | 1 |
| Lassen, JF | 1 |
| Husted, SE | 1 |
| Gunzenhauser, D | 1 |
| Sawitzki, H | 1 |
| Fung, S | 1 |
| Rodger, M | 1 |
| Desjardins, L | 1 |
| Douketis, J | 1 |
| Berge, E | 1 |
| Abdelnoor, M | 1 |
| Nakstad, PH | 1 |
| Sandset, PM | 1 |
| Chesebro, JH | 1 |
| Kontny, F | 1 |
| Fry, ET | 1 |
| Wallentin, L | 1 |
| Camm, AJ | 1 |
| Adams, HP | 1 |
| Strobbe, G | 1 |
| Pannier, D | 1 |
| Villain, A | 1 |
| Feutry, F | 1 |
| Marliot, G | 1 |
| Pautas, E | 1 |
| Gouin, I | 1 |
| Bellot, O | 1 |
| Andreux, JP | 1 |
| Siguret, V | 1 |
| Bath, PM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Randomized, Open-Label Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban (DU-176b) With Enoxaparin/Warfarin Followed by Warfarin Alone in Subjects Undergoing Planned Electrical Cardioversion of Nonvalvular Atrial F[NCT02072434] | Phase 3 | 2,199 participants (Actual) | Interventional | 2014-03-25 | Completed | ||
| The Use of Enoxaparin Compared to Unfractionated Heparin for Short Term Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing TEE Guided Cardioversion: Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II Randomized Mu[NCT00289042] | Phase 4 | 200 participants | Interventional | 1999-12-31 | Completed | ||
| Diagnostic Accuracy of the ATE Score for the Exclusion of Intra-atrial Thrombi Before Catheter Ablation of Atrial Fibrillation: a Confirmatory Study[NCT03455673] | 3,160 participants (Actual) | Observational | 2018-09-18 | Completed | |||
| A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796] | Phase 3 | 1,473 participants (Actual) | Interventional | 2006-12-31 | Active, not recruiting | ||
| An Open Label, Multi-center Trial to Evaluate the Feasibility and Safety of Short-term Treatment With Subcutaneously Injected Certoparin (8000 U Anti-Xa Twice Daily) in Patients With Persistent Nonvalvular Atrial Fibrillation[NCT00171769] | Phase 3 | 200 participants | Interventional | 2005-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02072434)
Timeframe: Randomization to end of follow-up (within 2 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Edoxaban | 0.5 |
| Warfarin | 1 |
(NCT02072434)
Timeframe: During treatment period (within 2 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Edoxaban | 1.5 |
| Warfarin | 1 |
(NCT02072434)
Timeframe: From randomization to the end of follow-up (within 2 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Edoxaban | 0.7 |
| Warfarin | 1.4 |
Patients with atrial thrombus diagnosed by pre-procedural transoesophageal echocardiography, without hypertension, heart failure, history of stroke and a plasma d-dimer level < 270 ng/ml ATE : Atrial Thrombus Exclusion minimum value = 0 maximum value = 4, patient at higher risk of atrial thrombus (NCT03455673)
Timeframe: at most 48 hours before ablation
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| ATE = 0, thrombus | ATE = 0, No thrombus | ATE > 0, thrombus | ATE > 0, No thrombus | |
| Atrial Fibrillation | 2 | 816 | 27 | 2227 |
9 reviews available for dalteparin and Atrial Fibrillation
| Article | Year |
|---|---|
Anticoagulant Therapy for Cancer-Associated Thrombosis : A Cost-Effectiveness Analysis.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Enoxaparin; | 2023 |
Anticoagulation Strategies in the Management of Lemierre Syndrome: A Systematic Review of the Literature.
Topics: Anticoagulants; Atrial Fibrillation; Disease Management; Drug Administration Schedule; Enoxaparin; H | 2021 |
The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Fema | 2021 |
[Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration S | 2013 |
Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment.
Topics: Acute Coronary Syndrome; Antithrombins; Atrial Fibrillation; Benzimidazoles; Chi-Square Distribution | 2013 |
Enoxaparin-induced spontaneous massive retroperitoneal hematoma with fatal outcome.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Enoxaparin; Fatal Outcome; Female; Hematoma; Humans; Retr | 2014 |
Anticoagulation with low-molecular-weight heparin in patients with heart diseases.
Topics: Anticoagulants; Atrial Fibrillation; Dalteparin; Enoxaparin; Heart Diseases; Heparin, Low-Molecular- | 2004 |
[Stroke and other thromboembolic complications of atrial fibrillation. Part VII. Prevention of cardioversion related thromboembolism].
Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Echocardiography, Transesophageal; El | 2005 |
[Anticoagulation with low molecular weight heparins within the framework of cardioversion for atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Echocardiography, Transesophageal; Electr | 2007 |
25 trials available for dalteparin and Atrial Fibrillation
| Article | Year |
|---|---|
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Electric Countershock; Enoxaparin; Factor Xa Inhibitors; | 2016 |
Health status outcomes after cardioversion for atrial fibrillation: results from the Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II Trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Echocardiography, Transesophageal; Electric Countershock; | 2008 |
Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation.
Topics: Antithrombin III; Atrial Fibrillation; Biomarkers; C-Reactive Protein; Echocardiography, Transesopha | 2008 |
Femoral vascular complications following catheter ablation of atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Catheter Ablation; Enoxaparin; Female; Femoral Artery; Hematoma | 2009 |
Prescribing patterns and outcomes of enoxaparin for anticoagulation of atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Data Collection; Dose-Response Relatio | 2003 |
A prospective and randomized comparison of the safety and effects of therapeutic levels of enoxaparin versus unfractionated heparin in chronically anticoagulated patients undergoing elective cardiac catheterization.
Topics: Aged; Anticoagulants; Antithrombin III; Atrial Fibrillation; Cardiac Catheterization; Enoxaparin; Fe | 2003 |
Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE)
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Drug Thera | 2004 |
Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using Enoxaparin (AC
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Electric Countershock; Enoxaparin; Hepari | 2007 |
The use of enoxaparin compared with unfractionated heparin for short-term antithrombotic therapy in atrial fibrillation patients undergoing transoesophageal echocardiography-guided cardioversion: assessment of Cardioversion Using Transoesophageal Echocard
Topics: Atrial Fibrillation; Echocardiography, Transesophageal; Electric Countershock; Enoxaparin; Feasibili | 2006 |
Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Decision Sup | 2007 |
Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT).
Topics: Administration, Oral; Aged; Ambulatory Care; Anticoagulants; Atrial Fibrillation; Blood Loss, Surgic | 2007 |
Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Enoxaparin; Female; Hemorrhage; Humans | 2007 |
Post-cardioversion transesophageal echocardiography (POSTEC) strategy with the use of enoxaparin for brief anticoagulation in atrial fibrillation patients: the multicenter POSTEC trial (a pilot study).
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Drug Administration Schedule; Echoc | 2007 |
Cost in the use of enoxaparin compared with unfractionated heparin in patients with atrial fibrillation undergoing a transesophageal echocardiography-guided cardioversion (from Assessment of Cardioversion using Transesophageal Echocardiography [ACUTE] II
Topics: Aged; Atrial Fibrillation; Costs and Cost Analysis; Echocardiography, Transesophageal; Electric Coun | 2008 |
Transesophageal echocardiography guided enoxaparin antithrombotic strategy for cardioversion of atrial fibrillation: the ACUTE II pilot study.
Topics: Anticoagulants; Atrial Fibrillation; Echocardiography, Transesophageal; Electric Countershock; Enoxa | 2000 |
Low molecular weight heparin for prevention of thromboembolic complications in cardioversion--rationale and design of the ACE study (Anticoagulation in Cardioversion using Enoxaparin).
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Atrial Fibrillation; Dose-Response Relationship, | 2002 |
Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dalteparin; Double-Blind Method; Femal | 2021 |
Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dalteparin; Double-Blind Method; Elective Surgical Proced | 2018 |
[The BRIDGE study].
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dalteparin; Double-Blind Method; Female; Humans; Injectio | 2016 |
A prospective, randomized, controlled trial of an emergency department-based atrial fibrillation treatment strategy with low-molecular-weight heparin.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Anticoagulants; Atrial Fibrillation; Combined Modality The | 2002 |
Is there a hypercoagulable phase during initiation of antithrombotic therapy with oral anticoagulants in patients with atrial fibrillation?
Topics: Administration, Oral; Aged; Atrial Fibrillation; Biomarkers; Blood Coagulation Factors; Dalteparin; | 2003 |
Anticoagulation with the low-molecular-weight heparin dalteparin (Fragmin) in atrial fibrillation and TEE-guided cardioversion.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Atrial Fl | 2003 |
Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin.
Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Atrial Fibrillation; Blood Loss, Surgical; Coh | 2004 |
Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; | 2000 |
Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antithrombin III; Atrial Fibrillation; Body Weight; Creatine; | 2002 |
62 other studies available for dalteparin and Atrial Fibrillation
| Article | Year |
|---|---|
Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation.
Topics: Analysis of Variance; Animals; Antithrombins; Atrial Fibrillation; Cell Proliferation; Dabigatran; F | 2017 |
An unusual adverse effect of nadroparin injections: Calcinosis cutis.
Topics: Adult; Amiodarone; Anticoagulants; Atrial Fibrillation; Biopsy; Calcinosis; Calcium; Enoxaparin; Hum | 2011 |
[Hypovolemic shock during surgery caused by a rectus sheath hematoma].
Topics: Adenoma; Anticoagulants; Atrial Fibrillation; Hematoma; Humans; Intraoperative Complications; Male; | 2005 |
Acute myocardial infarction in a patient with severe unrecognized mitral stenosis.
Topics: Analgesics; Anti-Arrhythmia Agents; Anticholesteremic Agents; Anticoagulants; Aspirin; Atrial Fibril | 2006 |
'Syringe-in-the-pocket'--a new approach to the outpatient thromboembolic prophylaxis of recurrent atrial fibrillation.
Topics: Aged; Ambulatory Care; Atrial Fibrillation; Electric Countershock; Feasibility Studies; Female; Fibr | 2007 |
Letter 2: Prevention of perioperative thromboembolism in patients with atrial fibrillation (Br J Surg 2007; 94: 1351-1355).
Topics: Anticoagulants; Atrial Fibrillation; Heparin; Humans; Intraoperative Complications; Nadroparin; Risk | 2008 |
Low molecular weight heparin (parnaparin) for cardioembolic events prevention in patients with atrial fibrillation undergoing elective electrical cardioversion: a prospective cohort study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Confidence Intervals; Electric Countershock; Female; Hepa | 2011 |
Safety and Efficacy of Direct Oral Anticoagulants in Patients With Moderate to Severe Cirrhosis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Enoxaparin; Hemorrhage; H | 2022 |
Trends in post-discharge prophylactic anticoagulant use among stroke patients in the United States between 2006 and 2019.
Topics: Aftercare; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dalteparin; Enoxaparin; Hep | 2022 |
Hemorrhagic Shock After Lumbar Puncture.
Topics: Anticoagulants; Atrial Fibrillation; Central Nervous System Diseases; Computed Tomography Angiograph | 2019 |
Transesophageal echocardiography-guided closure of electrically isolated left atrial appendage to constrain a rapidly growing thrombus despite anticoagulation and sinus rhythm.
Topics: Action Potentials; Aged, 80 and over; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Atrial | 2020 |
Bridging Anticoagulation Therapy: A Teachable Moment.
Topics: Accidental Falls; Aged; Anticoagulants; Atrial Fibrillation; Buttocks; Deprescriptions; Embolization | 2020 |
Comparing TEE- vs Non-TEE-guided cardioversion of atrial fibrillation: The ENSURE-AF trial.
Topics: Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Clinical Decision-Making; Duration of T | 2020 |
Ulcerative IgA vasculitis in the setting of warfarin therapy.
Topics: Anticoagulants; Atrial Fibrillation; Drug Substitution; Enoxaparin; Female; Glomerulonephritis, IGA; | 2020 |
Enoxaparin related spontaneous fatal retroperitoneal hemorrhage in a patient with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Drug Substitution; Enoxaparin; Fatal Outcome; Female; Hea | 2020 |
Direct oral anticoagulants versus enoxaparin in patients with atrial fibrillation and active cancer.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Enoxaparin; Heparin, Low-Molecular-Weight | 2021 |
A giant left atrial thrombus.
Topics: Anticoagulants; Atrial Fibrillation; Coronary Thrombosis; Echocardiography, Transesophageal; Enoxapa | 2017 |
The Perioperative Management of Antithrombotic Therapies Using Enoxaparin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Enoxaparin; Female; Heparin, Lo | 2017 |
Intravenous enoxaparin anticoagulation in percutaneous left atrial cardiac procedures.
Topics: Adult; Aged; Aged, 80 and over; Atrial Appendage; Atrial Fibrillation; Cardiac Catheterization; Card | 2017 |
Anticoagulation prescribing patterns in patients with cancer.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Hemorrhage; Humans; Middle | 2018 |
Leukocytoclastic vasculitis associated with rivaroxaban.
Topics: Aged, 80 and over; Atrial Fibrillation; Biopsy, Needle; Drug Eruptions; Enoxaparin; Female; Follow-U | 2018 |
Challenges of anticoagulation for atrial fibrillation in patients with severe sepsis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Enoxaparin; Female; Heparin; Humans; I | 2013 |
Anticoagulation therapy: Edoxaban noninferior to warfarin in patients with AF.
Topics: Anticoagulants; Atrial Fibrillation; Embolism; Enoxaparin; Female; Humans; Male; Stroke; Warfarin | 2014 |
Purple toes syndrome following stroke thrombolysis and warfarin therapy.
Topics: Acute Kidney Injury; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Embolism, Cholesterol; | 2014 |
[Perioperative control of vitamin K antagonists in elective surgery].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Elective Surgical Procedures; Enoxapar | 2014 |
The evolving role of dabigatran etexilate in clinical practice.
Topics: Antithrombins; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Cardiovascular Diseases; Clinic | 2015 |
Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience.
Topics: Acenocoumarol; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebra | 2016 |
Incidence and predictors of left atrial thrombus prior to catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cardiac Catheterization; Catheter A | 2009 |
Comparison of safety of subcutaneous enoxaparin as outpatient anticoagulation bridging therapy in patients with a mechanical heart valve versus patients with nonvalvular atrial fibrillation.
Topics: Aged; Ambulatory Care; Anticoagulants; Atrial Fibrillation; Cohort Studies; Enoxaparin; Female; Hear | 2009 |
Stroke prevention versus bleeding risk of vitamin-K antagonists: a double-edged sword in patients with atrial fibrillation who require surgery.
Topics: Anticoagulants; Atrial Fibrillation; Enoxaparin; Hemorrhage; Humans; Stroke; Vitamin K | 2009 |
Bridging of chronic oral anticoagulation with enoxaparin in patients with atrial fibrillation: results from the prospective BRAVE registry.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Enoxaparin; Female; Hemorrhage; Hum | 2009 |
Prevalence and clinical characteristics associated with left atrial appendage thrombus in fully anticoagulated patients undergoing catheter-directed atrial fibrillation ablation.
Topics: Adult; Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Catheter Ablation; Chi-Square Di | 2010 |
Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoagulation therapy in patients undergoing pacemaker and defibrillator implantation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cardiac Pacing, Artificial; Chronic Disease; Confidence I | 2010 |
Left atrial Lasso catheter thrombus aspiration.
Topics: Atrial Fibrillation; Catheter Ablation; Coronary Thrombosis; Enoxaparin; Female; Heart Atria; Humans | 2010 |
Transoesophageal echocardiography predictors of periprocedural cerebrovascular accident in patients undergoing catheter ablation of atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Case-Control Studies; Catheter Ablation; Echocardiography | 2010 |
[Persistent left atrial thrombus in atrial fibrillation under oral anticoagulation].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Anticoagulants; Atrial Fibrillation; Drug T | 2010 |
Fatal basilar artery occlusion under dabigatran occurring 13 days after femoral embolectomy.
Topics: Aged; Anticoagulants; Antithrombins; Arterial Occlusive Diseases; Atrial Fibrillation; Benzimidazole | 2012 |
Outcome of noncardiac and nonvascular surgery in patients with mechanical heart valves.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Case-Control | 2012 |
[Enoxaparin induced skin necrosis].
Topics: Aged; Anticoagulants; Atrial Fibrillation; Enoxaparin; Female; Humans; Necrosis; Skin; Skin Diseases | 2003 |
Retroperitoneal hematoma following rofecoxib and enoxaparin coadministration in a patient with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Comorbidity; Cyclooxygenase Inhibitors; Enoxaparin; Hemat | 2005 |
Pre- and post-cardioversion transesophageal echocardiography for brief anticoagulation therapy with enoxaparin in atrial fibrillation patients: a prospective study with a 1-year follow-up.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Echocardiography, Transesophageal; Electric Countershock; | 2005 |
Ruptured femoral pseudoaneurysm presenting as a lateral abdominal wall hematoma.
Topics: Abdominal Wall; Aged; Aneurysm, False; Anticoagulants; Atrial Fibrillation; Diagnosis, Differential; | 2005 |
Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Enoxaparin; Female; Heart Valve | 2005 |
Once atrial fibrillation, always oral anticoagulation?
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Electric Countershock; | 2007 |
Rectal sheath hematoma in an elderly woman after anticoagulation treatment.
Topics: Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Enoxaparin; Female; Hematoma; Humans; Rectal | 2006 |
[Stroke with leg paralysis -- cardioversion in atrial fibrillation: prevention of thromboembolism in risk patients].
Topics: Administration, Oral; Age Factors; Aged; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation | 2006 |
Massive subchorionic hematoma associated with enoxaparin.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Cesarean Section; Chorion; Enoxaparin; Factor Xa Inhibit | 2006 |
Quick, easy, and safe? On the use of low-molecular-weight heparins in cardioversion of atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Echocardiography, Transesophageal; Electric Countershock; Enoxa | 2006 |
Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; C-Reactive Protein | 2007 |
Withholding warfarin therapy for atrial fibrillation patients in the perioperative period.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Enoxaparin; Humans; Perioperative Care; Stroke; | 2008 |
Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low-molecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Echocardiography, Transesophageal; Elect | 2001 |
A new therapeutic strategy for electrical cardioversion of atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Clinical Protocols; Echocardiography, Transesophageal; El | 2001 |
Bridging with the Low molecular weight heparin certoparin in patients requiring temporary discontinuation of oral anticoagulation - the non-interventional, retrospective REMEMBER study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Female; Heparin, Low-Molecular-Weig | 2012 |
AFFECT: a prospective, open-label, multicenter trial to evaluate the feasibility and safety of a short-term treatment with subcutaneous certoparin in patients with persistent non-valvular atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Clinical Protocols; Drug Administration Schedule; Echocar | 2008 |
The Janus face of thromboprophylaxis in patients with high risk for both thrombosis and bleeding during intracranial surgery: report of five exemplary cases.
Topics: Aged; Atrial Fibrillation; Cerebral Hemorrhage; Coronary Artery Disease; Dalteparin; Fatal Outcome; | 2009 |
[Abdominal tumor after persistent coughing and uncontrolled anticoagulation].
Topics: Abdomen, Acute; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coloni | 2010 |
Emergency department-based atrial fibrillation treatment strategy with low-molecular-weight heparin.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Critical Pathways; Dalteparin; Emergency Service, | 2003 |
Anticoagulation interruptus: not without risk.
Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Blood Loss, Surgical; Carotid Arteri | 2004 |
Evaluating the place of low-molecular-weight heparin in the management of acute coronary syndromes. A panel discussion with audience participation.
Topics: Angina, Unstable; Anticoagulants; Atrial Fibrillation; Dalteparin; Heparin, Low-Molecular-Weight; Hu | 2001 |
Antiplatelet aggregating versus anticoagulant agents in preventing early recurrent stroke among patients with atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Dalteparin; Platelet Aggrega | 2001 |
First-time prescription of enzalutamide in a patient treated with fluindione and digoxin: serial drug interactions.
Topics: Aged; Atrial Fibrillation; Benzamides; Digoxin; Drug Interactions; Drug Overdose; Drug Substitution; | 2019 |
Atrial fibrillation, stroke, and acute antithrombotic therapy.
Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Randomized | 2003 |